Award reduced in Texas Vioxx case

Share this article:
A judge in a Texas lawsuit over Merck's Vioxx today reduced a $32 million jury award to $7.75 million, citing Texas' recently enacted caps on punitive damages, according to a story appearing on The Wall Street Journal's Web site.

The state jury in April found Merck liable for the death of Leonel Garza, a 71-year-old man who had a fatal heart attack within a month of taking the withdrawn painkiller. Merck was ordered to pay Garza's family $7 million in non-economic compensatory damages and $25 million in punitive damages.

But Judge Alex Gabert ordered the punitive damage reduced as required by state law. The law caps punitive damages at twice the amount of economic damages – lost pay—and up to $750,000 on top of non-economic damages. Because Garza was retired, the jury awarded no economic damages, so Merck was ordered to pay the most the family could receive under state law.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...